Core Viewpoint - The latest data from the Hong Kong Stock Exchange indicates that on December 24, shareholders of Innovent Biologics (01801) deposited shares worth HKD 45.98 billion, representing 3.31% of the total [1] Group 1: Company Developments - UBS reported that six new products from Innovent Biologics and a new indication for Tyvyt (sintilimab) have been included in the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] - Innovent Biologics has officially been included in the Hang Seng Index [1] Group 2: Analyst Ratings - UBS maintains a "Buy" rating for Innovent Biologics with a target price of HKD 137.4 [1]

Group 1 - The core announcement is that Zijin Mining International will be included in the Hang Seng Composite Index and its classification indices, effective after market close on October 15, with the inclusion taking effect on October 16 [1][3] - Zijin Mining International was officially listed on the Hong Kong Stock Exchange on September 30, with a closing price of HKD 120.6 per share, representing a 68.5% increase from the issue price of HKD 71.59 [3] - The stock price peaked at HKD 144.8 per share on October 3, before closing at HKD 136 per share [3] Group 2 - The company completed its listing process in a short timeframe, having submitted its application on June 30 and passing the hearing on September 14, leading to its listing on September 30 [3] - The total number of shares issued was approximately 349 million, with a total issuance amounting to HKD 25 billion, excluding the over-allotment option [3] - The company attracted significant interest from both domestic and international investors, with cornerstone investors accounting for 49.94% of the offering, including notable firms such as GIC, Hillhouse, BlackRock, Schroders, and Fidelity International, collectively subscribing to USD 1.6 billion (approximately HKD 12.5 billion) of the shares [3]